Enzymotec Ltd. (NASDAQ:ENZY) is set to issue its quarterly earnings data before the market opens on Tuesday, November 14th. Analysts expect the company to announce earnings of $0.10 per share for the quarter.
Enzymotec (NASDAQ:ENZY) last announced its quarterly earnings data on Wednesday, August 16th. The biotechnology company reported ($0.10) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.05 by ($0.15). Enzymotec had a negative net margin of 14.52% and a negative return on equity of 3.88%. The business had revenue of $13.00 million during the quarter, compared to analysts’ expectations of $12.78 million. During the same quarter in the previous year, the firm earned $0.04 earnings per share. Enzymotec’s revenue was up 11.1% on a year-over-year basis. On average, analysts expect Enzymotec to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Enzymotec Ltd. (ENZY) opened at $11.80 on Friday. Enzymotec Ltd. has a 52-week low of $5.20 and a 52-week high of $12.35.
Several brokerages have recently issued reports on ENZY. ValuEngine raised Enzymotec from a “sell” rating to a “hold” rating in a report on Saturday, August 12th. Zacks Investment Research raised Enzymotec from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 17th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $11.50 target price on shares of Enzymotec in a report on Thursday, October 19th. Finally, Wells Fargo & Company lifted their target price on Enzymotec from $9.50 to $12.00 and gave the stock a “market perform” rating in a report on Monday, October 30th. Four analysts have rated the stock with a hold rating, The company currently has a consensus rating of “Hold” and a consensus price target of $11.75.
An institutional investor recently raised its position in Enzymotec stock. State Street Corp lifted its position in Enzymotec Ltd. (NASDAQ:ENZY) by 1.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,952 shares of the biotechnology company’s stock after purchasing an additional 380 shares during the quarter. State Street Corp owned about 0.09% of Enzymotec worth $169,000 at the end of the most recent reporting period. Institutional investors own 26.46% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Enzymotec Ltd. (ENZY) to Release Quarterly Earnings on Tuesday” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2017/11/12/enzymotec-ltd-enzy-to-release-quarterly-earnings-on-tuesday.html.
Enzymotec Company Profile
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.